PEB
02/05/2014 11:04
GENERAL
REL: 1104 HRS Pacific Edge Limited
GENERAL: PEB: Pacific Edge Named Top Bioscience Company 2014
Pacific Edge named Top Bioscience Company in 2014
Pacific Edge has been named NZBIO's top bioscience company for 2014. Pacific
Edge was specifically recognised for building the profile and credibility of
biotechnology and biotechnology companies in New Zealand.
The announcement of the industry accolade this week is further recognition
for the Dunedin based cancer diagnostic company and comes a few months after
taking the Supreme Award at the NZ Innovation Council Awards.
Pacific Edge Chief Executive Office David Darling says the Company is
delighted to receive the recognition for the advances being made to the
clinical capability for the detection and management of cancers. The
company's Urine Sampling System is becoming a core element of the advances in
clinical utility, which can be used by the patient in-home to take a sample.
"It is rare in the biotechnology sector to have a company with the capability
and resources to go from discovery science all the way through clinical
trials and product development to finally making a commercial product as
Pacific Edge has done with Cxbladder - our molecular diagnostic test for
bladder cancer."
Cxbladder is a non-invasive test with the Company's easy to use Urine
Sampling System becoming a core element of the advances in clinical utility,
which allows patients can use at home. The sample is analysed in one of
Pacific Edge's laboratories for the tell-tale molecular markers that will
provide the urologist with information on the probability of the patient
having bladder cancer, or not.
Cxbladder is now available commercially in the United States through the
company's own CLIA and CAP regulated laboratory in Hershey, Pennsylvania. In
the later part of 2013 the company signed three large, preferred national
provider networks. These provider networks provide patients access to
healthcare services and technology by contracting with providers and payers
on a national basis. These three agreements signed with FedMed, ACPN and
Stratose give millions of Americans access to Cxbladder and its positive
benefits as a quick, cost effective, non-invasive and highly accurate cancer
detection test that is particularly appealing to US healthcare professionals,
patients, and insurers.
The custom built, commercial laboratory for Pacific Edge's US subsidiary
PEDUSA was completed in September 2012 to process Cxbladder samples, was
certified in 2013 by CLIA and more recently by CAP, to enable the laboratory
to offer Cxbladder as a Laboratory Developed Test (LDT) to clinicians and
physicians.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal
cancers and melanoma. The company has recently completed and released its
first product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to urologists in New Zealand, Australia, the US and
soon in Spain.
www.pacificedge.co.nz
ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its
wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge
Diagnostics USA Ltd, and selected commercial partners in Australia and Spain,
Healthscope and Oryzon respectively.
www.pacificedgedx.com
ABOUT Cxbladder
Cxbladder is a proprietary, accurate molecular diagnostic test that enables
the non-invasive detection of bladder cancer from a small volume of urine. It
provides general practitioners and urologists with a quick, cost effective
and accurate measure of the presence of the cancer, and provides urologists
with the opportunity to reduce their reliance on the need for invasive tests
such as cystoscopy. The recently published, Journal of Urology in September
2012, multi-centre international clinical study recruited 485 patients from
Australia and New Zealand.
Results show that Cxbladder out-performed all of the benchmark technologies
in the clinical trial and detected nearly all of the tumours of concern to a
urologist; At a performance of 82% sensitivity and 85% specificity the test
sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper
urinary tract cancers as well as greater than 95% of high grade tumours.
www.cxbladder.com
End CA:00250044 For:PEB Type:GENERAL Time:2014-05-02 11:04:07
